Popular Pre-Market Trades in US Stocks
Akari Therap, down 9.25% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
SKK up 7.91% in pre-market. Based on recent key news:
<ol>
<li>
On May 4, SKK Holdings announced the signing of an asset purchase agreement with Rantizo to acquire drone assets valued at approximately $258.8 million. This move makes SKK a publicly traded drone platform operator, driving the stock price up.
</li>
<li>
On May 5, SKK Holdings' stock price soared 736.53% on Monday afternoon, reaching a new 52-week high. This increase is directly related to the company's acquisition of drone assets.
</li>
<li>
On May 5, technical analysis showed that SKK's stock price is far above its moving average, with an RSI of 92.53, indicating an overbought condition that may lead to a price correction in the short term. The drone industry is growing rapidly, and market volatility is intensifying.
</li>
</ol>
Top Gainers in Pre-Market US Stocks
Entravision up 74.54% in pre-market. Based on recent key news:
<ol>
<li>
On May 5, Entravision released its first-quarter financial report, showing a year-on-year revenue growth of 114.4%, reaching $196.97 million, with a net profit of $12.36 million. This strong financial performance significantly boosted the stock price. Source: Reuters
</li>
<li>
On May 5, the company announced a GAAP earnings per share of $0.13 for the quarter, exceeding market expectations and further enhancing investor confidence. Source: Business Wire
</li>
<li>
On May 5, Entravision's local advertising revenue grew by 6%, despite a national advertising revenue decline of 18%, but overall performance remained strong. Source: Company press release. The advertising industry faces risks from policy changes and market volatility.
</li>
</ol>
Yidianxing up 63.16% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
Avalo Therapeutics up 53.54% in pre-market. Based on recent key news:
<ol>
<li>
On May 5, Avalo Therapeutics announced the successful completion of the primary endpoint of the LOTUS trial, causing the stock price to rise. The company also announced a public offering plan, further driving the stock price up.
</li>
<li>
On May 5, Avalo Therapeutics priced a $375 million public offering, with the stock price rising 48.5% in after-hours trading. The offering was priced at $17.75 per share and is expected to be completed on May 7
On May 5th, Avalo Therapeutics' stock price rose 18% in regular trading, with data from Benzinga showing its long-term momentum is strong, at the 93rd percentile. The biotechnology sector has performed well recently, with significant capital inflows
</li>
</ol>

AKTX

Akari Therap pre-market down 9.25%; SKK pre-market up 7.91%; Entravision Communications pre-market up 74.54%; Yidianxing pre-market up 63.16%; Avalo Therapeutics pre-market up 53.54%

Price Alert

Pre-market hot trades in US stocks: Akari Therap pre-market down 9.25%; SKK pre-market up 7.91%